Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 339.1 USD +0.01% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one LLY stock under the Base Case scenario is 230.5 USD. Compared to the current market price of 339.1 USD, Eli Lilly and Co is Overvalued by 32%.

The Intrinsic Value is calculated as the average of the two valuation methods:

LLY Intrinsic Value
Base Case
230.5 USD
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

LLY Profitability Score
Profitability Due Diligence

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Declining ROE
Positive 1-Year Revenue Growth
ROIC is Increasing
Positive ROIC
71/100
Profitability
Score

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

LLY Solvency Score
Solvency Due Diligence

Eli Lilly and Co's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Average D/E
Short-Term Liabilities
Long-Term Liabilities
67/100
Solvency
Score

Eli Lilly and Co's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
77%
Gross Margin
29%
Operating Margin
22%
Net Margin
19%
FCF Margin
66%
ROE
18%
ROIC
Other

LLY Capital Structure
Eli Lilly and Co

Market Capitalization 322B USD
Total Debt 14.1B USD
Minority Interest 95.8M USD
Preferred Equity 0 USD
Cash and Equivalents 2.6B USD
Short-Term Investments 125M USD
Enterprise Value 334B USD

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 397.31 USD with a low forecast of 270.68 USD and a high forecast of 462 USD.

Lowest
Price Target
270.68 USD
20% Downside
Average
Price Target
397.31 USD
17% Upside
Highest
Price Target
462 USD
36% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

LLY Competitors
Eli Lilly and Co

LLY Suppliers & Customers
Eli Lilly and Co

Eli Lilly and Co has 88 key suppliers from 13 countries and 14 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
48
Veeva Systems Inc
Health Care
Evercore Inc
Financial Services
Omnicom Group Inc
Media
Ampco-Pittsburgh Corp
Metals & Mining
Model N Inc
Technology
Pfizer Inc
Pharmaceuticals
Box Inc
Technology
Catalent Inc
Pharmaceuticals
Alexandria Real Estate Equities Inc
Real Estate
O
ON24 Inc
Technology
Donnelley Financial Solutions Inc
Financial Services
Athenex Inc
Biotechnology
Matthews International Corp
Commercial Services & Supplies
R
Royalty Pharma PLC
Pharmaceuticals
Regenxbio Inc
Biotechnology
T
Terns Pharmaceuticals Inc
Pharmaceuticals
Incyte Corp
Biotechnology
Context Therapeutics Inc
Pharmaceuticals
Halozyme Therapeutics Inc
Biotechnology
Veracyte Inc
Biotechnology
Precision BioSciences Inc
Biotechnology
Comcast Corp
Media
Certara Inc
Health Care
Vanda Pharmaceuticals Inc
Biotechnology
Karuna Therapeutics Inc
Biotechnology
Brooks Automation Inc
Semiconductors
N
NextCure Inc
Biotechnology
Rigel Pharmaceuticals Inc
Biotechnology
Zentalis Pharmaceuticals Inc
Biotechnology
Beyondspring Inc
Biotechnology
Nektar Therapeutics
Pharmaceuticals
Avidity Biosciences Inc
Biotechnology
Chinook Therapeutics Inc
Biotechnology
Sigilon Therapeutics Inc
Biotechnology
Quanterix Corp
Life Sciences Tools & Services
Myriad Genetics Inc
Biotechnology
OPKO Health Inc
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Leap Therapeutics Inc
Biotechnology
PureTech Health PLC
Biotechnology
Dicerna Pharmaceuticals Inc
Biotechnology
Spruce Biosciences Inc
Biotechnology
P
Pieris Pharmaceuticals Inc
Biotechnology
OPTIMIZERx Corp
Health Care
Qualys Inc
Technology
Harte Hanks Inc
Media
Anthera Pharmaceuticals Inc
Biotechnology
Dexcom Inc
Health Care
Suppliers Map

Eli Lilly and Co has 42 key customers from 8 countries and 6 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

Eli Lilly and Co insiders have sold more shares than they have bought in the past 12 months.

During the last 12 months Eli Lilly and Co insiders bought 249k USD , and sold 1.4B USD worth of shares. The last transaction was made on Feb 6, 2023 by Lilly Endowment Inc (10 percent owner), who sold 18.3M USD worth of LLY shares.

Sold
0-3
months
101M USD
1
3-6
months
224M USD
3
6-9
months
536M USD
2
9-12
months
536M USD
4
Bought
0-3
months
0
0 USD
3-6
months
1
200k USD
6-9
months
0
0 USD
9-12
months
1
49.8k USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
101M USD
N/A
-101.2M
6 Months
325M USD
200k USD
-324.8M
9 Months
861M USD
200k USD
-861.1M
12 Months
1.4B USD
249k USD
-1.4B
Purchases
22
Sales
2 856
No transactions found
Why is insider trading important?

Shareholder Return

LLY Price
Eli Lilly and Co

1M 1M
-7%
6M 6M
+12%
1Y 1Y
+41%
3Y 3Y
+141%
5Y 5Y
+377%
Annual Price Range
339.1
52w Low
233.14
52w High
374.76
Price Metrics
Average Annual Return 40.76%
Standard Deviation of Annual Returns 22.21%
Max Drawdown -12%
Shares Statistics
Market Capitalization 322B USD
Shares Outstanding 950 177 984
Percentage of Shares Shorted 0.71%

Company Profile

Eli Lilly and Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

322B USD

Dividend Yield

1.32%

Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

Contact

INDIANA
Indianapolis
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
+13172762000.0
https://www.lilly.com/

IPO

1970-07-09

Employees

35 000

Officers

Chairman, CEO & Pres
Mr. David A. Ricks
Sr. VP & CFO
Ms. Anat Ashkenazi
Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs
Dr. Daniel M. Skovronsky M.D., Ph.D.
Sr. VP & Chief Information and Digital Officer
Mr. Diogo Rau
Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology
Mr. Jacob S. Van Naarden
Chief Accounting Officer & VP of Fin.
Mr. Donald A. Zakrowski
Show More
VP of Fin. & Special Projects
Mr. Martin Bott MIBS
Sr. VP, Gen. Counsel & Sec.
Ms. Anat Hakim J.D.
Sr. VP and Chief Ethics & Compliance Officer
Mr. Alonzo Weems
Sr. VP of Corp. Affairs & Communications
Ms. Leigh Ann Pusey
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 230.5 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 339.1 USD, Eli Lilly and Co is Overvalued by 32%.